Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation

Detalles Bibliográficos
Autores principales: Xu, Jianlin, Yang, Haitang, Jin, Bo, Lou, Yuqing, Zhang, Yanwei, Zhang, Xueyan, Zhong, Hua, Wang, Huiming, Wu, Dan, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Corrigenda
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131290/
https://www.ncbi.nlm.nih.gov/pubmed/27905549
http://dx.doi.org/10.1038/srep38270
_version_ 1782470865632362496
author Xu, Jianlin
Yang, Haitang
Jin, Bo
Lou, Yuqing
Zhang, Yanwei
Zhang, Xueyan
Zhong, Hua
Wang, Huiming
Wu, Dan
Han, Baohui
author_facet Xu, Jianlin
Yang, Haitang
Jin, Bo
Lou, Yuqing
Zhang, Yanwei
Zhang, Xueyan
Zhong, Hua
Wang, Huiming
Wu, Dan
Han, Baohui
author_sort Xu, Jianlin
collection PubMed
description
format Online
Article
Text
id pubmed-5131290
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-51312902016-12-15 Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation Xu, Jianlin Yang, Haitang Jin, Bo Lou, Yuqing Zhang, Yanwei Zhang, Xueyan Zhong, Hua Wang, Huiming Wu, Dan Han, Baohui Sci Rep Corrigenda Nature Publishing Group 2016-12-01 /pmc/articles/PMC5131290/ /pubmed/27905549 http://dx.doi.org/10.1038/srep38270 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Corrigenda
Xu, Jianlin
Yang, Haitang
Jin, Bo
Lou, Yuqing
Zhang, Yanwei
Zhang, Xueyan
Zhong, Hua
Wang, Huiming
Wu, Dan
Han, Baohui
Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
title Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
title_full Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
title_fullStr Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
title_full_unstemmed Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
title_short Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
title_sort corrigendum: egfr tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the l858r point mutation
topic Corrigenda
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131290/
https://www.ncbi.nlm.nih.gov/pubmed/27905549
http://dx.doi.org/10.1038/srep38270
work_keys_str_mv AT xujianlin corrigendumegfrtyrosinekinaseinhibitorsversuschemotherapyasfirstlinetherapyfornonsmallcelllungcancerpatientswiththel858rpointmutation
AT yanghaitang corrigendumegfrtyrosinekinaseinhibitorsversuschemotherapyasfirstlinetherapyfornonsmallcelllungcancerpatientswiththel858rpointmutation
AT jinbo corrigendumegfrtyrosinekinaseinhibitorsversuschemotherapyasfirstlinetherapyfornonsmallcelllungcancerpatientswiththel858rpointmutation
AT louyuqing corrigendumegfrtyrosinekinaseinhibitorsversuschemotherapyasfirstlinetherapyfornonsmallcelllungcancerpatientswiththel858rpointmutation
AT zhangyanwei corrigendumegfrtyrosinekinaseinhibitorsversuschemotherapyasfirstlinetherapyfornonsmallcelllungcancerpatientswiththel858rpointmutation
AT zhangxueyan corrigendumegfrtyrosinekinaseinhibitorsversuschemotherapyasfirstlinetherapyfornonsmallcelllungcancerpatientswiththel858rpointmutation
AT zhonghua corrigendumegfrtyrosinekinaseinhibitorsversuschemotherapyasfirstlinetherapyfornonsmallcelllungcancerpatientswiththel858rpointmutation
AT wanghuiming corrigendumegfrtyrosinekinaseinhibitorsversuschemotherapyasfirstlinetherapyfornonsmallcelllungcancerpatientswiththel858rpointmutation
AT wudan corrigendumegfrtyrosinekinaseinhibitorsversuschemotherapyasfirstlinetherapyfornonsmallcelllungcancerpatientswiththel858rpointmutation
AT hanbaohui corrigendumegfrtyrosinekinaseinhibitorsversuschemotherapyasfirstlinetherapyfornonsmallcelllungcancerpatientswiththel858rpointmutation

Ejemplares similares